Charles River Laboratories International, Inc. (CRL)
| Previous Close | 239.77 |
| Open | 240.71 |
| Bid | 242.15 x 1400 |
| Ask | 242.79 x 1000 |
| Day's Range | 239.50 - 243.50 |
| 52 Week Range | 181.36 - 349.84 |
| Volume | |
| Avg. Volume | 622,109 |
| Market Cap | 12.282B |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | 33.80 |
| EPS (TTM) | 7.20 |
| Earnings Date | Feb 14, 2023 - Feb 20, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 270.17 |
- Zacks
Charles River (CRL) to Report Q4 Earnings: What's in Store?
The broad-based demand and meaningful price increases in the RMS business particularly in North America are expected to have contributed to Charles River's (CRL) top line in Q4.
- Business Wire
Charles River Laboratories Acquires SAMDI Tech
WILMINGTON, Mass., January 30, 2023--Charles River Laboratories Acquires SAMDI Tech
- GlobeNewswire
iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of
